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Abstract
Neoadjuvant and adjuvant chemotherapies provide survival beneﬁts to breast cancer patients, in particular in estrogen
receptor negative (ER−) cancers, by reducing rates of recurrences. It is assumed that the beneﬁts of (neo)adjuvant
chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here,
we provide experimental evidence that ER− breast cancer cells that survived high-dose Doxorubicin and Methotrexate based
chemotherapies elicit a state of immunological dormancy. Hallmark of this dormant phenotype is the sustained activation of
the IRF7/IFN-β/IFNAR axis subsisting beyond chemotherapy treatment. Upregulation of IRF7 in treated cancer cells
promoted resistance to chemotherapy, reduced cell growth and induced switching of the response from a myeloid derived
suppressor cell-dominated immune response to a CD4+/CD8+ T cell-dependent anti-tumor response. IRF7 silencing in
tumor cells or systemic blocking of IFNAR reversed the state of dormancy, while spontaneous escape from dormancy was
associated with loss of IFN-β production. Presence of IFN-β in the circulation of ER− breast cancer patients treated with
neoadjuvant Epirubicin chemotherapy correlated with a signiﬁcantly longer distant metastasis-free survival. These ﬁndings
establish chemotherapy-induced immunological dormancy in ER− breast cancer as a novel concept for (neo)adjuvant
chemotherapy activity, and implicate sustained activation of the IRF7/IFN-β/IFNAR pathway in this effect. Further, IFN-β
emerges as a potential predictive biomarker and therapeutic molecule to improve outcome of ER− breast cancer patients
treated with (neo)adjuvant chemotherapy.
Introduction
Chemotherapy is widely used for the treatment of breast
cancer. While estrogen receptor negative (ER−) or triple-
negative breast cancer (TNBC) is generally associated with
unfavorable prognosis, neoadjuvant and adjuvant che-
motherapies provide signiﬁcant survival beneﬁts to about
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one third of these patients [1]. In case of progression, ER−
breast cancers relapse with a bimodal distribution, with
peaks at 1–2 years and 4–5 years after surgery, followed by
a tailed extension up to 10 years [2, 3]. This proﬁle suggests
that disseminated tumor cells (DTC) evolve with a dis-
continuous growth kinetics [3, 4]. Viable, dormant DTC and
micro-metastases have been identiﬁed in animal models [5,
6] and breast cancer patients [7]. Hence, the concept of
tumor dormancy was introduced, whereby surviving cancer
cells remain quiescent and clinically silent for prolonged
periods of time before resuming growth and causing
clinically-manifest relapses. While long term dormancy has
been typically associated with ER+ breast cancer due to their
late relapses, the discontinuous growth kinetics of relapses in
ER− cancers suggests that a dormancy also applies to ER−
[4, 8, 9]. Three non-mutually exclusive forms of cancer
dormancy have been described: cellular dormancy, whereby
cancer cells enter a state of cell cycle arrest (i.e., G0-G1) and
survive as disseminated single cells or small cell clusters; [9]
angiogenic dormancy, a state where cancer cells proliferate
but die of starvation due to lack angiogenesis; [10] immu-
nological dormancy, in which disseminated cancer cells are
kept under control by the immune system [9] in a process
referred to as cancer immune-editing [11]. This consists of
three phases: elimination, when cancer cells are recognized
and killed by the immune system; equilibrium, when the
immune system controls but does not completely eliminate
malignant cells, and escape, when residual tumor cells avoid
immune control and resume growth [11, 12]. Mechanisms
underline immunological dormancy in solid tumors,
including breast cancer, are not well characterized.
Recently, chemotherapy-induced anti-tumor immune
responses have been reported [13]. Emerging evidence
indicates that tumor inﬁltrating lymphocytes (TILs) actively
contribute to the response to chemotherapy and clinical
outcome in breast cancer [14, 15]. This is particularly
relevant to TNBC as these cancers are inﬁltrated by TILs,
particularly CD8+ T-cells [14, 16, 17], In TNBC, elevated
TIL levels are associated with an improved pathological
complete response following chemotherapy [18], decreased
rates of recurrences and improved survival [14, 17, 19].
TILs inﬁltration in TNBC and HER2+ breast cancers is
being considered as a potential biomarker with prognostic
and predictive values [20].
Type I interferons (IFNs) are potent regulators of the
immune response, including in cancer [21, 22]. High level of
type I IFN-regulated MxA protein closely relates to TILs
inﬁltration and is an independent prognostic factor for
disease-free survival in TNBC [23]. Type I IFN signaling is
up-regulated in tumors responding to chemotherapy, persisted
in residual tumor cells in patient-derived xenografts (PDX)
[24] and is necessary for the efﬁcacy of some chemotherapies
[25]. However, the expression of a type I IFN-related DNA-
damage resistance signature (IRDS) was reported to correlate
with resistance to chemotherapy and radiotherapy in multiple
cancer types, including of the breast [26, 27].
Here we show that ER− breast cancer cells surviving
chemotherapy induced a strong T cell response mediating
immunological tumor dormancy. Activation of the IRF7/
IFN-β/IFNAR pathway is critical in this process.
Results
In vitro chemotherapy treatment durably alters
in vitro and in vivo 4T1 cell growth
In order to expose tumor cells to chemotherapy under well
controlled conditions, we treated the metastatic triple-negative
murine mammary adenocarcinoma cell line 4T1 in vitro with
two drugs used for ER− breast cancer treatment: the anti-
metabolite Methotrexate (MTX), and the anthracycline Dox-
orubicin (DOX) [1, 28, 29]. To simulate maximum tolerated
dose (MTD) chemotherapy, 4T1 cells were treated over
2–3 weeks’ time with doses killing over 85% of the cells
(IC85) within 48 h (Supplementary Fig. 1a), until surviving
colonies formed (Fig. 1a). Two of the obtained lines were
named MR20 (MTX resistant at 20 ng/ml) and DR500 (DOX
resistant at 500 ng/ml), respectively (Supplementary Fig. 1b).
The in vitro growth of these cells was slower compared to
parental 4T1 cells (Supplementary Fig. 1c). When implanted
orthotopically into the 4th mammary fat pad (MFP) of
immune competent syngeneic BALB/c mice, 4T1 cells
formed rapidly growing and metastatic tumors, DR500 cells
formed growing tumors but with rare lung metastasis (Fig.
1b–e) and MR20 cells did not form any tumors or lung
metastasis within the usual time frame (Fig. 1f–i).
MR20 cell dormancy in immunocompetent mice
In MR20-injected mice, however, some tumors formed
starting one month after implantation and at 3.5 months, 6
out of 10 mice (60%) had primary tumors (Fig. 1j) and lung
metastases (Fig. 1k). The remaining mice (40%) remained
tumor-free for over one-year without evidence of tumor
cells in the MFP at sacriﬁce. These results are reminiscent
of the discontinuous kinetics seen in patients after initial
therapy and consistent with a state of dormancy [3, 4, 30].
Taken together, these results demonstrate that 4T1 cells
that survived high-dose DOX or MTX chemotherapy
in vitro formed latent, dormant tumors in vivo. While in
MR20 cells dormancy occurred in primary tumor and
metastasis, in DR500 cells dormancy was evident in
metastasis only. To investigate the mechanism of dormancy,
we focused mainly on MR20 cells since dormancy was
already evident at the primary site.
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MR20 cells are cell cycle proﬁcient but show
increased apoptosis in vitro
To characterize the reduced MR20 cell growth in vitro we
ﬁrst analyzed expression of the proliferation marker Ki67.
This was expressed in over 95% of MR20 and 4T1 cells
(Supplementary Fig. 2a, b). Cell cycle analysis indicated no
difference in the distribution of the cycle phases, including
no increase in the G0/G1 fraction typical of cellular dor-
mancy (Supplementary Fig. 2c, d). However, we observed a
higher proportion of MR20 apoptotic cells by Annexin V
and active Caspase 3 staining compared to 4T1 cells (9.95%
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vs. 4.8%) (Supplementary Fig. 2e, f). In addition 4T1 cells
lose the CMFDA membrane labeling faster than MR20 cells
(110 vs. 44 times diluted, respectively) (Supplementary
Fig. 2g).
These results indicate that chemotherapy-resistant MR20
cells have no slower cell cycle progression but increased
rate of apoptosis compared to 4T1 cells. While these
alterations exclude cellular dormancy, they do not explain
their latency and delayed growth in vivo.
MR20 cells induce a T and B cell-prevalent immune
response while 4T1 cells promote expansion of
MDSCs
To characterize the in vivo tumor dormancy, we ﬁrst con-
sidered the angiogenic potential of MR20 cells. However,
as there was no detectable tumor mass in MR20-injected
MFP within the ﬁrst 25 days (Fig. 1f), we could not eval-
uate tumor angiogenesis [10]. Instead, we noticed a
remarkable enlargement of the MFP-draining lymph node
(LN) in MR20 cell-injected mice (Supplementary Fig. 3a).
Histological analysis excluded LN metastatic colonization
(Supplementary Fig. 3b). The total cell number in the MFP-
draining LN increased from 1.1 × 107 cells, in saline-
injected mice, to 2.5 × 107 cells in MR20-injected mice
(Supplementary Fig. 3c). Next, we characterized the
immune cells in the MFP and in the circulation of BALB/c
mice injected with MR20 and 4T1 tumor cells. MR20-
injected MFPs had very few MDSCs (Gr1+CD11b+ cells),
similar to naive mice even after 30 days post injection,
while 4T1-injected MFPs showed high MDSCs levels,
increasing over time (Fig. 2a). Conversely, MR20-injected
mice harbored signiﬁcantly more dendritic cells (CD11b
+CD11c+), CD4+, CD8+ T and B lymphocytes, particularly
at later time points (Fig. 2a). A similar increase of these
cells was detected in the blood (Fig. 2b). These results
suggest that MR20 cells induce a profound alteration of the
local and systemic immune response: from a MDSC-
dominated response in 4T1-injected mice to a DC, T and B
cell-prevalent response in MR20-injected mice.
DR500 cells induce a weaker immune response but
higher frequency of cytotoxic CD8+ T lymphocytes
at the dormant metastatic site compared to MR20
cells
DR500 cells formed primary tumors but did not form lung
metastases (Fig. 1b–h). To unravel possible differences
between DR500 and MR20 tumor cells in their capacity to
elicit an immune response in vivo, we characterized the
immune cells in the primary tumor, in the circulation and in
the lungs of BALB/c mice injected with DR500 vs. MR20
and 4T1 injected mice. At day 15, DR500 tumor cells
induced changes similar to those induced by MR20 cells
(decrease in Gr1+D11b+ cells, increased in CD4+, CD8+ T
and B lymphocytes) at the three sites, but to a lesser extent.
At day 24 the DR500 suppressive effect on Gr1+CD11b+
cells disappeared and the inductive effect on CD4+, CD8+
T and B lymphocytes was attenuated at all sites, particularly
in the primary tumor, compared to MR20-injected mice
(Supplementary Fig. 4a, b, c). As DR500 injected mice
were nevertheless free of lung metastases, we monitored
expression of the cytotoxic molecules FasL, GranzymeB
and IFNγ in CD8+T cells in the lungs of these mice. We
observed a higher frequency of cytotoxic molecules in both
DR500 and MR20 models compared to 4T1-injected mice
but with some differences. The lungs of DR500-injected
mice had more FasL, GranzymeB and IFNγ - positive CD8
+ T cells, particularly at day 24, while in MR20-injected
mice the cytotoxic response was observed at earlier time
point (Supplementary Fig. 5).
Altogether these results suggest that DR500 cells elicit
similar immune response at MR20 cells but of lesser
magnitude. At the metastatic site both models show similar
cytotoxic differentiation of CD8+ T cells.
CD4+ and CD8+ lymphocytes are required for MR20
dormancy
We next asked the question whether the adaptive immune
response and in particular T cells were indeed functionally
involved in promoting MR20 dormancy. To this end, we
Fig. 1 Breast cancer cell treatment with high-dose chemotherapy
in vitro induces tumor dormancy in vivo. a Experimental design of
chemotherapy treatment of tumor cells in vitro. b Primary tumor
growth in BALB/c mice injected with 4T1 and DR500 tumor cells (n
= 8/group). c–d Quantiﬁcation of tumor weight c (n= 8) and lung
metastatic nodule numbers (d) (n= 8) at day 28 post injection in the
mice of panel b. e Illustrative sections of lungs from mice injected with
4T1 and MR20 tumor cells 25 days post injection (H&E staining).
Asterisks denote presence of metastasis (scale bar: 1 mm). f Primary
tumor growth in BALB/c mice injected with 4T1 and MR20 tumor
cells (n= 8). g–h Quantiﬁcation of tumor weight (g) and lung meta-
static nodule numbers (h) at day 28 post injection in the mice of panel
(f) (n= 8). i Illustrative sections of lungs from mice injected with 4T1
and MR20 tumor cells 28 days post injection (H&E staining). Aster-
isks denote presence of metastasis (scale bar: 1 mm). j Long-term
monitoring of tumor development in BALB/c mice injected with
MR20 cells. Each tumor growth curves correspond to one individual
mouse as indicated (n= 10/group). 4T1 tumor growth (black curve) is
shown as the average tumor volume of 8 mice. These mice are
sacriﬁced at day 25 due to large tumor volume. k Representative
sections of lung metastases detected in MR20-injected mice upon
progression (H&E staining). Asterisks denote presence of metastasis
(scale bar: 1 mm). Data are represented as mean ± SEM. P values: * <
0.05; *** < 0.0005, unpaired two-tailed Student’s t test
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injected MR20 cells into immune-compromised NOD-
SCID common gamma 2 chain-deﬁcient (NSG) mice that
lack mature T, B and NK cells and display impaired DC and
macrophage functions [31]. MR20 cells efﬁciently formed
primary tumors and lung metastases in NSG mice (Fig. 3a,
b). To demonstrate the involvement of CD4+ or CD8+ T
lymphocytes in controlling MR20 dormancy, we injected
MR20 cells into BALB/c mice depleted of CD4+ or CD8+
Fig. 2 MR20 tumor cells in vivo suppress MDSC mobilization and
promote T and B lymphocyte accumulation. a Top: Scheme of the
protocol used for the analysis of the immune response upon orthotopic
MR20 injection into BALB/c mice indicating days of blood collection
and tumor removal for ﬂow cytometry analysis. Graphs: Percentages
of immune cells in the primary tumor site from saline buffer, 4T1-
injected or MR20-injected BALB/c mice detected by ﬂow cytometry
analysis. b Percentages of immune cells in the peripheral blood from
saline buffer, 4T1-injected or MR20-injected BALB/c mice detected
by ﬂow cytometry analysis. Time points of analysis (days after tumor
cells’ injection) are indicated. Data are from one representative
experiment. n= 5/group. Results are expressed as % of CD45+ cells.
Data are represented as mean ± SEM. P values: * < 0.05; ** < 0.005;
*** < 0.0005 by unpaired two-tailed Student’s t test
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T lymphocytes by antibody treatment (Fig. 3c, left panel).
Depletion of either CD4+ or CD8+ T lymphocytes (con-
ﬁrmed by ﬂow cytometry, data not shown), resulted in
effective tumor growth (Fig. 3c, right panel). Further we
tested whether MR20 cells elicit a protective immune
response by injecting MR20 cells in the 4th MFP 10 days
before injecting 4T1 parental cells into the contralateral
MFP. Preconditioning of mice with MR20 cells reduced
4T1 tumor growth by approximately 50% (Fig. 3d).
These results indicate that CD4+ and CD8+ T lymphocytes
contribute to enforce chemotherapy-induced MR20 tumor
dormancy in vivo. The “vaccination effect” of immune pre-
conditioning with MR20 cells suggests that dormancy is not
due to the emergence of chemotherapy-induced neo-antigens.
Fig. 3 MR20 tumor cell dormancy in vivo requires CD4+ or CD8+
lymphocytes. a Growth curve of MR20-derived tumors injected in
NSG and BALB/c mice. n= 5–8/group. b Quantiﬁcation of lung
metastasis nodules in the mice of experiment in panel a. Micrographs
show representative histological sections of mice lungs from the three
groups in panel a (H&E staining). Scale bar: 1 mm. c Antibody
treatment protocol for CD4+, CD8+ T cell-depletion (left) and MR20
tumor growth curve in IgG isotype control BALB/c injected mice or
CD4+-T Lymphocyte, CD8+-T Lymphocyte-depleted BALB/c mice
(right). n= 6/group. d Graphical scheme of 4T1 and MR20 tumor cell
injection in the three groups of BALB/c mice (left): Group 1, 4T1-
injected mice; Group 2, MR20-injected mice; Group 3, MR20-injected
mice 10 days before day 0 of 4T1 injection into contralateral 4th MFP.
n= 8/group. Data are represented as mean ± SEM. P values: ** <
0.005; *** < 0.0005 by unpaired two-tailed Student’s t test
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The transcriptomes of chemotherapy treated,
dormant tumor cells are enriched for type I IFN
response genes
To unravel the molecular basis for the distinct behavior of
chemo-treated cells, we performed transcriptome analyses
of 4T1, MR20 and DR500 cells. Unsupervised clustering
analysis revealed signiﬁcant differences in the gene
expression. Statistical analysis identiﬁed 324 and 535 (>2-
fold) signiﬁcantly up-regulated and 234 and 680 (<−2-fold)
down-regulated genes in MR20 and DR500 cells compared
to 4T1 cells, respectively (Supplementary Table). Both
MR20 and DR500 cells were enriched for transcripts of
innate and adaptive immune responses, speciﬁcally the type
I IFN-related signature (Fig. 4a, b and Supplementary Fig.
6a, b). No changes in the expression of transcripts of the
main angiogenic pathways were observed, further suggest-
ing that MR20 tumor dormancy was unlikely due to deﬁ-
cient angiogenesis. Transcription factors analysis identiﬁed
the interferon regulatory factor 7 (IRF7) as most sig-
niﬁcantly up-regulated in MR20 (Fig. 4c) and DR500 cells
(Supplementary Fig. 6c). The upregulation of expression of
IRF7 itself, and of IRF9, the signal transducer and activator
of transcription (STAT) 1 and 2 were conﬁrmed by RT-
qPCR in both MR20 and DR500 cells (Fig. 4d, e). To test
whether chemotherapy treatment was able to directly induce
IRF7 expression in different cell lines, we treated murine
(4T1 and D2A1) and human (MDA-MB-231 and MDA-
MB-468) breast cancer cell lines for 24 h with high doses
(IC85) of MTX and DOX. Indeed, we observed up-
regulation IRF7, IRF9, STAT1 and STAT2 expressions
(Fig. 4f, g).
We conclude that MTX and DOX chemotherapies acti-
vate type I IFN signaling, which, in surviving cells (MR20,
DR500) persists beyond treatment. The expression of IRF7,
IRF9, STAT1, and STAT2 in DR500 cells is weaker com-
pared to MR20 cells.
Constitutive type I IFN pathway activation in
spontaneously dormant tumor cells
The sustained upregulation of type I IFN signaling in dor-
mant tumor cells raised the question of whether the same
mechanism is associated with other models of dormancy.
To address this question, we used D2A1 and D2.0R cells
that were originally derived from spontaneous mammary
tumors from a hyperplastic alveolar nodule line. They
represent different stages of tumor progression: D2A1 cells
are tumorigenic and metastatic while D2.0R are less
tumorigenic and form metastases only after long latency
times and are considered a model for breast cancer dor-
mancy (Supplementary Fig. 7a). Despite their divergent
behavior in vivo, these cells lines readily proliferate in vitro
[5, 32, 33].
IRF7, IRF9, STAT1, and STAT2 transcripts were up-
regulated in dormant D2.0R cells relative to D2A1 cells
(Supplementary Fig. 7b). In D2.0R-injected mice we
observed a decrease in Gr1+CD11b+ cells and an accu-
mulation of CD4+ and B lymphocytes or NK cells com-
pared to D2A1 (Supplementary Fig. 6c).
From these data, we conclude that activation of type I
IFN signaling pathway also occurs in the D2.0R model of
spontaneous tumor dormancy.
IRF7 silencing sensitizes tumor cells to
chemotherapy in vitro and breaks dormancy in vivo
To functionally validate the role of IRF7 in tumor dor-
mancy, we stably silenced IRF7 expression in MR20 and
D2.0 R tumor cells by lentiviral-mediated shRNA trans-
duction (Supplementary Fig. 8a, b). IRF7 silencing also
decreased the expression of IRF9, STAT1 and STAT2 tran-
scripts (Supplementary Fig. 8a, b), consistent with pub-
lished observations [34]. IRF7-silenced cells were more
sensitive to MTX and proliferate faster compared to non-
silenced (NS) MR20 and D2.0R controls (Supplementary
Fig. 8c, d, e, f). Importantly, when injected into immune
competent BALB/c mice, IRF7-silenced MR20 and D2.0R
cells formed growing (Fig. 5a–e) and metastatic (Fig. 5b–f)
tumors. Analysis of the immune cells at the tumor site and
in peripheral blood 30 days post injection, revealed that
IRF7 silencing caused an increase in Gr1+CD11b+ cells
and a decrease in CD4+, CD8+ T and B lymphocytes in
both models (Fig. 5c–h).
Taken together, these results demonstrate that elevated
expression of IRF7 promotes tumor resistance against
chemotherapy and switches the MDSCs-dominated
response into a T and B cell-prevalent immune response
maintaining dormancy.
IFN-β mediates IRF7-dependent tumor dormancy
As IRF7 is a key transcriptional regulator of type I IFN
expression [35], we considered type I IFNs as potential
effectors of dormancy. To test this hypothesis, we ﬁrst
measured IFN-α and-β levels in culture supernatants of 4T1,
DR500, MR20, MR20 KD-IRF7 and 4T1 cells treated for
24 h with MTX. IFN-β level was very low (<1 pg/ml) in the
supernatant of 4T1 cells but high (over 40-fold increase) in
the supernatants of MR20 cells and MTX-treated 4T1 cells,
and IRF7 silencing in MR20 cells decreased IFN-β levels
(Fig. 6a). DR500 cells secreted IFN-β at much lower levels
compared to MR20 cells (7 vs. 40 pg/ml) (Fig. 6b). IFN-α
levels were uniformly low (<10 pg/ml) in all tested
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Fig. 4 MR20 cells are enriched for type I IFN genes. a Heat map of the
signature score of the hallmarks pathway analysis in 4T1 and MR20
cells color-coded based on expression levels relative to average
(Violet, downregulated; yellow, upregulated). Results from biological
triplicate are shown. b Heat-map of type I IFN signature-related gene
expression in 4T1 cells and MR20 cells, color-coded based on
expression levels relative to average (blue, down-regulated; red, up-
regulated). The gene list was taken from MSigDB. c Top list of
enriched transcription factors in MR20 vs. 4T1 cells. d–e Relative
expression of IRF7, IRF9, STAT1, STAT2 transcripts in d 4T1 and
MR20 cells, (e) 4T1 and DR500 cells. f–g Relative expression analysis
by RT-qPCR of IRF7, IRF9, STAT1, STAT2 mRNAs in f 4T1 and
D2A1 murine tumor cells or g MDA-MB-231(MDA-231) and MDA-
MB-468(MDA-468) human tumor cells treated with MTX or DOX for
24 h at the indicated IC85 doses. Data are represented as mean ± SEM.
P values: * < 0.05; ** < 0.005; *** < 0.0005; **** < 0.0001 by
unpaired two-tailed Student’s t test
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conditions (Fig. 6c). Signiﬁcantly higher levels of IFN-α
and-β were detected in the supernatants of D2.0R cells
compared to D2A1 cells (Supplementary Fig. 9a, b), and
IRF7 silencing in D2.0R cells suppress IFN-β production
(Supplementary Fig. 9a). These results suggest a potential
correlation between type I IFN production and dormancy.
Further, we monitored type I IFN receptor (IFNAR)
expression and function. Flow cytometry analysis revealed
Fig. 5 Silencing of IRF7 expression breaks tumor dormancy. a and e
Growth curve of tumors in BALB/c mice injected with a MR20 cells
silenced for IRF7 (KD-IRF7) or non-silenced cells (NS). n= 10/group.
or e D2.0R cells silenced for IRF7 (KD-IRF7) or non-silenced cells
(NS). n= 8/group. b and f Quantiﬁcation of lung metastases in mice of
experiment in panel a or e and representative images of histological
lung sections (H&E staining). Asterisks denote presence of metastases.
n= 10/group. Scale bar: 1 mm. c and d Frequency of immune cells in
the primary tumor site (c) or peripheral blood (d) determined by ﬂow
cytometry analysis from BALB/c mice injected with 4T1, MR20 NS
and IRF7-silenced MR20 (MR20 KD-IRF7) cells. n= 5/group. g and
h Frequency of immune cells in the primary tumor site (g) or per-
ipheral blood (h) determined by ﬂow cytometry analysis from BALB/c
mice injected with D2A1, D2.0R NS and IRF7-silenced D2.0R
(D2.0R KD-IRF7) cells. n= 5/group. Results are expressed as % of
CD45+ cells and represent mean values. Data are represented as mean
± SEM. P values: * < 0.05; ** < 0.005; *** < 0.0005; **** < 0.0001
by unpaired two-tailed Student’s t test and two-way ANOVA
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that 4T1, D2A1, MR20, and D2.0R cells express IFNAR
with a trend toward higher expression in dormant cells
(Supplementary Fig. 9c). We then exposed 4T1 or
D2A1 cells to exogenous IFN-β or IFN-α (50 ng/ml for 24
h) and observed increased expression of IRF7, IRF9,
STAT1, and STAT2 transcripts (Supplementary Fig. 9d, e).
Conversely, culture of MR20 cells in the presence of a
blocking antibody against the α subunit of IFNAR (i.e.,
IFNAR1) reduced IRF7, IRF9, STAT1 and STAT2 expres-
sion (Fig. 6d). These results demonstrate functional and
autocrine activation of the IFN-β/IFNAR/IRF7 pathway in
4T1 and MR20 cells. Consistent with these results, the IFN-
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β levels in the serum of MR20 cell-injected mice, 7 days
post-injection, was higher compared to levels in 4T1 cell-
injected mice (Fig. 6e). To investigate the direct effect of
IFN-β on dormancy in vivo, we treated MR20-bearing mice
with the anti-IFNAR1 blocking antibody. This resulted in
the formation of MR20-derived tumors (Fig. 6f) associated
with increased MDSCs and reduced CD4+ and CD8+ T
lymphocyte inﬁltration (Fig. 6g). Interestingly, MR20 cells
(A1, A3 and B2) that escaped dormancy in vivo (See Fig.
1j) no longer secrete IFN-β, further supporting a direct role
for IFN-β expression in maintaining dormancy (Supple-
mentary Fig. 8f).
Altogether, these results indicate that an active IFN-β/
IFNAR/IRF7 pathway is critical to maintain dormancy in vivo.
Presence of IFN-β in the serum of ER− breast cancer
patients during Epirubicin neoadjuvant
chemotherapy is associated with longer distant
metastasis-free survival
To test whether activation, or lack thereof, of the IFN-β/
IFNAR1/IRF7 pathway during chemotherapy might corre-
late with a better, or worse outcome, respectively, we
determined IFN levels in the serum of 51 ER− breast cancer
patients of the trial of principle (TOP) study [36] treated
with neoadjuvant Epirubicin chemotherapy. Measurements
were performed at time of diagnosis (T1), after the ﬁrst
cycle (T2), and 3–4 weeks after the last cycle (T3) of
chemotherapy, before surgery (Fig. 7a). IFN-α was unde-
tectable in most patients (data not shown). IFN-β levels
were heterogeneous (from undetectable to high) across
patients and within individual patients at the three time
points (Fig. 7b), although average IFN-β levels at T3 were
lower compared to levels detected at T1 and T2 (Fig. 7c).
Patients were stratiﬁed for the presence or absence of
detectable IFN-β and then analyzed for distant metastasis-
free survival (DMFS). Lack of detectable IFN-β correlated
with shorter DMFS at all time points with a statistically
signiﬁcant difference at T2 (Hazard ratio= 0.28, 95%
conﬁdence interval: 0.08–0.99, p= 0.049) (Fig. 7d). No
signiﬁcant correlations were observed between IFN-β levels
at the three time points with IRF7 and IFNB1 gene
expression and published immune gene expression sig-
natures in the primary tumor before therapy including the
IRF7 signature by Bidwell et al. predicting longer bone
metastasis-free survival [34, 37–39]. This suggests that the
evidence of the immune response, as captured by the pre-
sence of IFN-β in serum during chemotherapy, cannot be
inferred from gene expression, including IFNB1, in the
treatment-naïve primary tumors (Fig. 7e).
From these data, we conclude that the presence of cir-
culating IFN-β in patients during neoadjuvant chemother-
apy correlates with a longer DMFS, independently of
IFNB1 expression levels and immune signatures in the
tumor before therapy.
Discussion
In this work, we demonstrate that sustained activation of the
IFN-β/IFNAR/IRF7 signaling axis in chemotherapy-treated
ER− breast cancer cells instigates immunological dor-
mancy. Upregulated IRF7 expression in treated cancer cells
is responsible for reduced cell growth, suppressed mobili-
zation of CD11b+Gr1+ MDSCs, increased expansion of
DCs, T and B lymphocytes and chemoresistance. This
immune-phenotype translates into an effective anti-tumor
immune response, which keeps treated cells dormant
(MR20) at the primary injection site and/or decreases
metastasis formation (DR500). Conversely, the inactivation
of this pathway breaks tumor dormancy, engendering
relapses and metastatic progression (Fig. 8). We could
corroborate these experimental ﬁndings in ER− breast
cancer patients by showing that lack of detectable IFN-β in
serum during treated Epirubicin neoadjuvant chemotherapy
correlates with a shorter DMFS.
The treatment of tumor cells in vitro and the choice of
drugs was guided by the following reasons: Firstly, to have
full control of dose and timing of drug exposure; Secondly,
to allows for complete recovery of treated and surviving
cells; Thirdly, to limit therapy-induced mutagenesis and
appearance of neo-epitopes we included Methotrexate, an
antimetabolite standard of care in combination treatments in
TNBC in the past, and still in used today [29, 40]; Fourthly,
Fig. 6 Interferon β/IFNAR axis mediates IRF7-dependent MR20
tumor dormancy. a–b, a IFN-β levels in the conditioned culture
supernatant of 4T1 untreated (NT) and 4T1 MTX-treated tumor cells
(90 nM for 24 h), MR20 NS non-silenced, IRF7-silenced MR20
(MR20 KD-IRF7) tumor cells and DR500 (b) tumor cells determined
by ELISA. c IFN-α levels in the conditioned culture supernatant of
4T1 untreated (NT) and 4T1 MTX-treated tumor cells (90 nM for 24 h)
or MR20 NS non-silenced and IRF7-silenced MR20 (MR20 KD-
IRF7) tumor cells determined by ELISA. d Relative expression of
IRF7, IRF9, STAT1 and STAT2 transcripts in 4T1 and MR20 tumor
cells cultured for 24 h in the presence of a blocking-antibody against
IFNAR1 subunit (20 ng/ml I.P.) or its IgG isotype control. e Levels of
IFN-β in the serum of BALB/c mice 7 days after injection of 4T1 and
MR20 tumor cells (into the MFP) determined by ELISA. f Growth
curve of MR20-injected BALB/c mice systemically treated with anti-
IFNAR1 blocking-antibody, its control IgG or no antibody, as indi-
cated. n= 8/group. g Analysis of immune cells in the peripheral blood
of MR20-injected BALB/c mice treated with anti-IFNAR1 blocking-
antibody, its control IgG or no antibody, as indicated. Blood analysis
performed by ﬂow cytometry at days 9, 15 and 35 post tumor injec-
tion. Data are from one representative experiment. Results are
expressed as % of CD45+ cells and represent mean values. n= 5/
group. Data are represented as mean ± SEM. P values: * < 0.05; ** <
0.005; *** < 0.0005; **** < 0.0001 by unpaired two-tailed Student’s t
test and one-way ANOVA
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we included Doxorubicin to test a class of drug (anthracy-
cline) widely used in TNBC also as single therapy [28, 40].
Some chemotherapies have been shown to induce the
anti-tumor immune response in cancer patients [13, 41]. For
example, Ma et al., reported that anthracycline-based che-
motherapy induces the release of ATP by dying tumor cells,
which promotes the recruitment and differentiation of
antigen presenting cells in the tumor microenvironment
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[42]. The role of Type I IFN in promoting response to
chemotherapy in tumor cells has been recently reported [24,
25]. Furthermore, expression of MHC class II antigen pre-
sentation pathways in tumor tissue is associated with better
outcome in TNBC patients, consistent with a protective
antitumor immune response [43]. Conversely, IFN-α deﬁ-
cient dendritic cells (DC) accumulating in aggressive breast
cancers favor the expansion of Tregs, suggesting that IFN-α
deﬁciency may contribute to tumor immune tolerance and
poor clinical outcome [44]. These improved immediate anti-
tumor effects of chemotherapy by the immune response
may be explained by enhanced tumor cell death, senescence
and cytotoxicity trigged by the rapid activation of type I
IFN response during chemotherapy [25, 41, 45]. However,
the long-term protective effects of chemotherapy as
observed in (neo)adjuvant chemotherapy, and the latency
(dormancy) before relapses, could not be explained by
immediate anti-tumor effects but only when considering the
non-linear kinetics of relapses, including in ER− cancers
[4, 8, 9].
Our work has two important implications. Firstly, it
establishes chemotherapy-induced immunological dor-
mancy in (ER-) breast cancer as a novel concept for how
(neo)adjuvant chemotherapy may act to provide long-term
survival beneﬁts. Strikingly, in spite of the fact that
immunological dormancy is a widely recognized form of
dormancy [46], there is paucity of data in the literature
characterizing the mechanisms involved. This may be due
to the limited availability of syngeneic dormant cell lines of
solid cancer and by the fact that grafting human cell lines or
patients-derived xenografts into immune deﬁcient mice
excludes the possibility to study the role of the adaptive
immune system. Experimental models of dormancy, how-
ever, exist in hematologic malignancies such as lymphoma
and leukemia [47]. Secondly, it implicates type I IFN
response in this effect. Previous studies based on tumor-
derived IFN signatures indicate that IFN-regulated genes
may correlate with favorable outcomes. We have previously
reported in patients that a pretreatment STAT1 signature
was associated with better prognosis in TNBC and HER2+
breast cancers [37] and with better response to neoadjuvant
chemotherapy [48]. High IRF7 pathway activity in primary
breast cancer predicted bone relapse-free survival in patients
and protected against bone metastasis in mice, and treat-
ment with IFN-α improved bone metastasis-free survival
[34]. High level of IFN-β activates STAT1, STAT2 and
STAT3 to facilitate cellular dormancy in tumor-
repopulating melanoma cells [49]. Our work signiﬁcantly
extends these observations by demonstrating that cells (i.e.,
MR20 and DR500) that survived chemotherapy treatment
maintained high expression levels of IRF7, IRF9, STAT1
and STAT2 even in the absence of the drugs. Consistently
with these observations, in vivo IFNAR1 blockade restored
a tumor-promoting immune response and broke dormancy
of MR20 cells. These results extend the implication of the
role of type I IFN in immunoediting in cancer [21, 22].
Although both MR20 and DR500 show similar increased
immune response, they also show different in vivo pheno-
type. DR500 cells have a weaker activation of the IRF7/IFN
response, which translates into a lesser effect on the
immune response compared to MR20 tumor-bearing mice.
The stronger immune response against MR20 in vivo
Fig. 7 Absence of circulating IFN-β in breast cancer patients at time of
neoadjuvant chemotherapy correlates with a shorter DMFS. a Scheme
of the experimental design for the analysis of IFN-β in breast cancer
patients’ sera. Time points are: T1, baseline before chemotherapy at
time of tumor diagnosis; T2, after the ﬁrst cycle of chemotherapy; T3,
after the last cycle of chemotherapy and before tumor surgery. C1-C4
represent therapy cycles (3 weeks interval). b IFN-β levels measured in
breast cancer patients of the TOP study at T1, T2 and T3 time points. c
Comparison of median IFN-β levels at the different time points. IFN-β
levels at T3 are lower compared to levels at T1 and T2. Results
represent median values (bar), quantile 0.25 and quantile 0.75 (box)
and extremes (lines). d Kaplan-Meier curves of probability of distant
metastasis-free survival (DMFS) in treated breast cancer patients
stratiﬁed for absence (0, black curve) or presence (1, red curve) of
systematic IFN-β at T1, T2, and T3 time points, respectively. e Matrix
analyzing potential correlations between IFN-β levels in patients’ sera
(at T1, T2, T3 time points), IFNB1 and IRF7 expression in the tumor
and four published immune/IRF7/STAT1 gene expression signatures
derived from tumors at time of diagnosis
Fig. 8 Illustrative scheme of the proposed model of chemotherapy-
induced dormancy. Primary breast tumor cells escape immune elim-
ination by inducing the expansion of immunosuppressive MDSC cells.
Chemotherapy treatment of primary breast tumor induces a type I IFN
response in tumor cells resulting in an autocrine and self-sustained
increased IRF7 expression, IFN-β secretion triggering IFNAR sig-
naling. IRF7/IFN-β stimulate the expansion of CD4+ and CD8+ T
lymphocytes and prevent the mobilization of MDSC cells thereby
switching the immune response from immunosuppressive (leading to
tumor relapse) to anti-tumoral (leading to tumor dormancy)
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suppressed the outgrowth both in primary site and distant
organs, while the weaker activation of IRF7/IFN response
in DR500 cell was only able to suppress the metastatic
growth in lung consistent with the observation by Bidwell
et al. [34]. In line with this notion, we observed that CD8+
T cells in lung of DR500-injected and 4T1-injected mice
express a higher levels of cytotoxicity markers.
Although activation of the IRF7/IFN-β/IFNAR pathway
contributes to cancer cell resistance against chemotherapy,
the fraction of cancer cells surviving chemotherapy is small
(15% after 48 h and much less at later time points) in spite
of rapid (i.e., within 24 h) activation of the pathway. This
implies that most cells die initially and only a few survived
to develop a phenotype eliciting dormancy. The study by
Weichselbaum et al. has shown that expression of IRDS is a
predictive marker for chemotherapy and radiation resistance
for breast cancer [26]. The author propose that the resistant
cells are selected for the failure to transmit cytotoxic signal
and instead results in a pro-survival signals. Based on these
considerations we propose that activation of the IRF7/IFN-
β/IFNAR pathway contributes to the selection of cells
resistance to chemotherapy (and eliciting an immune
response) but is not sufﬁcient to protect the bulk of the
cancer cells initially exposed to chemotherapy. The link
between IRF7/IFN pathway and tumor resistance remains
elusive at this point, which will be further studied.
In accordance with preclinical observations, we found
that the absence of detectable IFN-β in the serum of TNBC
patients during (i.e., T2) neoadjuvant chemotherapy treat-
ment signiﬁcantly correlated with a shorter DMFS. This
also suggests that measuring immune-related parameters
during (neo)adjuvant therapy may represent an additional
method to obtain valuable predictive/prognostic information
complementing pretreatment information. Altogether these
data demonstrate that MR20-derived IFN-β promotes
chemotherapy-induced dormancy. Interestingly, we
observed that the spontaneously dormant D2.0R cells have
an active IRF7/IFN-β axis and elicit an immune response
similar to the one observed in chemotherapy-treated MR20
and DR500 cells. This raises the intriguing possibility that
some forms of dormancy occurring during tumor evolution
may be due to spontaneous IRF7/IFN-β axis activation.
Cancer stem cell (CSC) has been proposed to be
responsible for therapy-resistance and relapse [50]. Recent
study by Liu et al. [51]. showed that chemotherapy trig-
gered tumor-independent expression of CCR2 by mono-
cytes induces cancer stemness in both HER2+ and TNBC.
Along with the studies by others [25, 42], the work of Liu
et al. conﬁrms that different immune cells may exerts dif-
ferent roles during chemotherapy, including tumor sup-
pressive and tumor promoting effects, some of which may
involve induction of stemness. Furthermore, IFN-I has
recently been recently shown to control stemness in the
Neu/T mouse tumor model [52]. The population of ALDH+
cancer stem cells was increased upon IFNAR mutation or
blocking of IFN-1 [52]. From the transcriptomic data, we
found that the stem cell markers Abcg2, Sca-1, and CD61
were upregulated both in MR20 and DR500, while Aldh1
and additional CSC-related markers (i.e., CD24, CD90,
CD29, CD133, CD166) were not. Further studies will be
necessary to better characterize MR20 and DR500 cells for
functional CSC-like properties.
In conclusion, we report a novel, valuable preclinical
model of chemotherapy-induced dormancy in ER- breast
cancer. With this model, we demonstrate the contribution of
the immune system in chemotherapy-induced dormancy
and identiﬁed activation of the IRF7/IFN-β/IFNAR axis as
critical mechanism involved. These results further support
the critical role of type I IFN response in immunoediting in
cancer [21, 22]. They also identify IFN-β as potential pre-
dictive biomarker and therapeutic molecule to improve
outcome of ER- breast cancer patients treated with (neo)
adjuvant chemotherapy.
Material and methods
Reagents and chemicals
Growth factor reduced Matrigel Matrix (MG) was obtained
from Becton Dickinson (BD Biosciences, Basel, Switzer-
land). Collagenase I was purchased from Worthington
(Lakewood, United Kingdom). Bovine serum albumin
(BSA), crystal violet (CV) and paraformaldehyde (PFA)
were obtained from Sigma-Aldrich (Buchs, Switzerland).
Anti-CD4, anti-CD8 and anti-IFNAR antibodies and IgG
control antibody were purchased from Bio X cell (New
Hampshire, USA). Chemotherapeutic drugs Doxorubicin
and Methotrexate, were generously provided by the Centre
Pluridisciplinaire d’Oncologie (now Department of Oncol-
ogy), University Hospital, University of Lausanne, Lau-
sanne, Switzerland.
Generating chemo-resistant tumor cells in vitro
106 tumor cells were plated in 10 cm cell culture dish
overnight before treatment. For Methotrexate selection,
cells were treated with the dosage around IC85 in culture
medium. The medium with Methotrexate were replaced in
2nd and 3rd day and then every 2–3 days. The treatment
was continued for up to 2 weeks until single colonies of
surviving cells were visible. For Doxorubicin selection, no
cells survived after treatment with the dosage of IC85. The
selection was performed with the dosage IC50 (0.05 µM)
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for one week. The surviving cells were further cultured with
0.2 µM, 0.75 µM, and 0.93 µM (500 ng/ml) consecutively
for 1 week in each dosage. After selection cells were then
cultured in normal medium for additional 2 weeks for
recovery.
Tumor models
4T1, MR20, DR500, D2A1, and D2.0R tumor cells (5 × 104
cells for 4T1, MR20 and DR500 and 105 for D2A1, D2.0R
in 50 μl PBS/10% Matrigel mixture per mouse) were
injected in the fourth right inguinal mammary gland of 6–7
week-old BALB/c, nude (nu/nu) (Harlan Laboratories,
Gannat, France; Charles River Laboratories, L’Arbresle,
France) and NSG (NOD SCID common gamma 2 chain
deﬁcient) female mice (University of Lausanne, Lausanne,
Switzerland). Blocking IFNAR antibody was injected
intraperitoneally (i.p.). We injected 10 mg/kg of antibody
on days 0, 3, 8, and 15 post tumor cell injection. Prior to
surgery, animals were anesthetized by an intra-peritoneal
injection of ketamine (1.5 mg/kg) and xylazine (150 mg/kg)
(both from Graeub, Bern, Switzerland). Tumor growth was
measured twice a week with caliper and tumor volume was
calculated by the equation: volume= (length × width2) × π/
6. At the endpoint mice were sacriﬁced according to deﬁned
ethical criteria. Mice were killed by CO2 inhalation fol-
lowed by neck dislocation. Tumors and lungs were resected,
incubated over-night in 4% PFA and parafﬁn-embedded for
sectioning [53]. All animal procedures were performed in
accordance with the Swiss and French legislations on ani-
mal experimentation and approved by the Cantonal Veter-
inary Service of the Cantons Vaud and Fribourg for
experiments in Lausanne and Fribourg.
Statistical analyses (except for microarray-based
gene expression analyses)
Data are presented as mean ± SEM from at least 3 inde-
pendent experiments, unless otherwise indicated. Statistical
comparisons were performed by an unpaired Student’s t test
with a two-tailed distribution or one-way ANOVA analysis
of variance with Bonferroni post-test, using Prism 7.0
GraphPad Software, Inc.
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